Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Reservoir Clear all
Completed Phase 1Phase 2 Interventional Results available

The Effect of Ixazomib on the Latent HIV Reservoir

NCT02946047
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG, Ixazomib 4 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 12, 2026, 11:44 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

NCT05612178
View directory record Official record
Conditions
HIV-1
Interventions
3BNC117-LS, 10-1074-LS, Sterile Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Not applicable Interventional Results available

Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals

NCT01286259
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Disulfiram
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

NCT02384395
View directory record Official record
Conditions
HIV, Acute HIV Infection
Interventions
Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

NCT01935089
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 12, 2026, 11:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

CAR-T Cells for HIV Infection

NCT04648046
View directory record Official record
Conditions
HIV Infections
Interventions
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Drug · Biological · Other
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 4 Interventional Results available

HIV Persistence and Viral Reservoirs

NCT01025427
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Raltegravir, tenofovir/emtricitabine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 1 Interventional

Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People

NCT02191098
View directory record Official record
Conditions
HIV, Stable ART
Interventions
ALT-803
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 12, 2026, 11:44 AM EDT
Withdrawn Phase 4 Interventional

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

NCT02990312
View directory record Official record
Conditions
Hiv, Kidney Transplant, HIV Reservoir, CCR5
Interventions
Sirolimus + Maraviroc
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 1 Interventional

Daclizumab to Treat HIV-Infected Patients

NCT00080431
View directory record Official record
Conditions
HIV Infections
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 12, 2026, 11:44 AM EDT
Terminated Phase 2 Interventional Results available

HIV Reservoir Reduction With Interleukin-2

NCT03308786
View directory record Official record
Conditions
HIV Infection
Interventions
Recombinant Interleukin-2
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Not applicable Interventional Results available

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

NCT00884793
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, Study NNRTI, Study PI
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 12, 2026, 11:44 AM EDT
Terminated No phase listed Observational

Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

NCT01319526
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
DNA analysis, RNA analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 12, 2026, 11:44 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

NCT02176135
View directory record Official record
Conditions
HIV
Interventions
Auranofin
Drug
Lead sponsor
Vaccine and Gene Therapy Institute, Florida
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 12, 2026, 11:44 AM EDT
Completed No phase listed Observational

IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment

NCT03416790
View directory record Official record
Conditions
HIV-1-infection
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
13 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 4 Interventional Results available

Efavirenz (EFV) Intensification

NCT07193875
View directory record Official record
Conditions
HIV
Interventions
Efavirenz 600mg
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View directory record Official record
Conditions
HIV-1-infection
Interventions
PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
Biological · Device
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 12, 2026, 11:44 AM EDT
Recruiting Phase 1 Interventional

Dasatinib for HIV-1 Reservoir Reduction

NCT07342491
View directory record Official record
Conditions
HIV Infections
Interventions
Dasatinib, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 12, 2026, 11:44 AM EDT
Recruiting Phase 2 Interventional

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

NCT05419024
View directory record Official record
Conditions
HIV
Interventions
Acute Treatment Interruption
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

Romidepsin Plus 3BNC117 Phase 2a Study

NCT02850016
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
3BNC117, Romidepsin
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Phase 2 Interventional

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

NCT03837756
View directory record Official record
Conditions
HIV-1-infection
Interventions
Saline, Lefitolimod, 3BNC117 and 10-1074
Drug
Lead sponsor
University of Aarhus
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 12, 2026, 11:44 AM EDT
Terminated Phase 4 Interventional Results available

Dolutegravir in Reservoirs

NCT02924389
View directory record Official record
Conditions
HIV
Interventions
dolutegravir, Triumeq, Truvada
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 12, 2026, 11:44 AM EDT
Completed Not applicable Interventional

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

NCT00051831
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 12, 2026, 11:44 AM EDT
Recruiting Phase 1 Interventional

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

NCT06819176
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Lenacapavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 12, 2026, 11:44 AM EDT